Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Gliclazide has greater glucose lowering efficacy than glibenclamide among type 2 diabetes mellitus patients with minor haplotype (K23/A1369) at the KCNJ11/ABCC gene locations.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Khoo Teck Puat Hospital
• Treatments: Gliclazide; Glyburide

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Age 21-65

• HbA1c >8.0% on two consecutive visits

Exclusion Criteria:

• Currently taking insulin at a regime more complex than basal insulin

• Not willing to perform self-blood glucose monitoring (SBGM)

• Renal impairment i.e. eGFR<50mls/min

• Pregnancy or unwilling to practice adequate contraception

• Taking other medications that may affect blood glucose e.g. systemic glucocorticoids.